Talk:Interferon gamma
 | The contents of the Interferon type II page were merged into Interferon gamma on 25 December 2022. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
| ||||||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Interferon gamma.
|
This article was the subject of a Wiki Education Foundation-supported course assignment, between 5 January 2022 and 11 March 2022. Further details are available on the course page. Student editor(s): Immcarle165 (article contribs).
Merger proposal edit
I propose merging Interferon type II into Interferon gamma. IFN gamma is the only member of the Interferon type II class, so information for the category and its sole member can easily be merged. The existing Interferon gamma page is the more comprehensive of the two, in my judgment. MrMSDS (talk) 15:40, 12 January 2022 (UTC)
- Completely agree - IFN gamma being the only Type IIIFN, the terms are today synonymous. 173.54.127.110 (talk) 17:06, 3 November 2022 (UTC)
Therapeutic uses edit
Exactly how important is the brassica comment - it is not about interferon gamma and should be removed. Clearly an example of a scientist with a big ego trying to put their own work into wikipedia. 195.195.98.99 (talk) 17:30, 3 November 2008 (UTC) H
Move discussion in progress edit
There is a move discussion in progress on Talk:Interferon, alpha 1 which affects this page. Please participate on that page and not in this talk page section. Thank you. —RMCD bot 07:59, 15 May 2013 (UTC)
Requested move 4 April 2016 edit
- The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review. No further edits should be made to this section.
The result of the move request was: Both moved. The first move restores the title which was agreed in a previous RM until it was moved without discussion earlier this year. The second has not been discussed or moved before, but the proposed name appears to be more common, is a better fit per MOS:ABBREVIATION, and also in the sprit of the aforementioned multi-move at Talk:Interferon alpha-1. No oppose votes after a full listing, so going ahead with the move. (non-admin closure) — Amakuru (talk) 12:33, 12 April 2016 (UTC)
– Correct scientific nomenclature, full name in plain English. Mimi 822 453 233 (talk) 20:29, 4 April 2016 (UTC)
- The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page or in a move review. No further edits should be made to this section.